MR-Linacs enable daily functional imaging to be performed in patients being treated with radiotherapy. In this work, the diffusion sequence developed by the MRL Consortium biomarkers working group underwent technical validation, showing accurate and repeatable phantom ADC measurements. Daily, whole-prostate ADC mapping was also performed in patients undergoing treatment for prostate cancer on an MRL. No significant differences were observed in whole-prostate ADC during the course of treatment for conventional and stereotactic ablative body radiotherapy (SABR) treatments. Absence of significant change in ADC could be related to the fact that patients were treated with neo-adjuvant hormone therapy prior to radiotherapy.
This abstract and the presentation materials are available to members only; a login is required.